Arcticzymes Technologies Asa · OSL:AZT
Arcticzymes Technologies Asa — Biotec Pharmacon — Q1 2019 Earnings Presentation
19 slides from Arcticzymes Technologies Asa's earnings presentation, Apr 30, 2019
Slide 1: Q1 2019 Presentation
Q1 2019 Presentation 30.04.2019, Oslo
Slide 2: Agenda
Agenda • Highlights • Q1 • ArcticZymes • BetaGlucans • Woulgan® • Other BetaGlucans segments • Q1 Financials • Outlook for 2019 2
Slide 3: Biotec Pharmacon
Biotec Pharmacon • Focused on specialized, novel enzyme and immunomodulating beta-glucan technology. • Two divisions, driving revenues and cash generation across USA, Europe and Asia: • ArcticZymes develops, manufactures and commercializes novel recombinant enzymes for use in molecular research, In
Slide 4: Highlights Q1 2019
Highlights Q1 2019 Sales & Gross profit 25 000 • Growth in all high margin areas compared to Q1 Sales 2018. 20 000 Gross profit • EBITDA of MNOK -3,9 compared to MNOK -5.1 Q1 2018, driven by sales and cost control. 15 000 • ArcticZymes launched a new product, Ligases, in line with strategy. 10 000 •
Slide 5: ArcticZymes
ArcticZymes wet). BIOTEC So PHARMACON
Slide 6: ArcticZymes Updates
ArcticZymes Updates • Commercial achievements • ArcticZymes Polymerases attract broader customer interests in all 3 market area: Molecular Research, In Vitro Diagnostics and more recently Therapeutics. • Therapeutic applications has evolved beyond Salt Active Nuclease where several other of ArcticZy
Slide 7: Innovation & strategic initiatives
Innovation & strategic initiatives Innovation: • ArcticZymes launched its first ligase enzyme - A High Quality T4 DNA ligase • A prototype panel of novel ligases has been provided to selected customers for evaluation. The outcome of the evaluation will prioritise the launch of our 1st novel ligase d
Slide 8: BetaGlucans
BetaGlucans Woulgan®, Adjuvant, Consumer Health, Animal Health
Slide 9: Status Woulgan
Status Woulgan® • Sales results during the latest 6 months are encouraging and Q1 sales closed at NOK 1,2 million, surpassing the 1 million mark for the first time. • An increasing number of key Germany distributors serviced by BBG are showing stable re-ordering patterns. • A new distribution agreem
Slide 10: Adjusted Woulgan Strategy
Adjusted Woulgan Strategy ® • Promoting SBG as the active ingredient will be the core argument going forward. It is the SBG that “activates macrophages and the innate immune system” allowing wounds to heal faster, when combined with moist healing properties. In general there seems to be a market tre
Slide 11: Other BetaGlucans Segments
Other BetaGlucans Segments Adjuvant study with MSKCC in New York: • The study is continuing to recruit patients at a good pace, where almost 230 of the planned 260 patients are included by end of Q1. • The two-arm study is designed to isolate and document the effect of our SBG® Consumer Health: • Go
Slide 12: Q1 Financials
Q1 Financials ites. BIOTEC ret” PHARMACON
Slide 13: Cash Flow from operations
Cash Flow from operations Net Cash position 40 000 Amounts in NOK 1.000' First quarter changes in cash of -3.5 MNOK: • 13.2 (13.2) MNOK in short-term 35 000 30 000 receivables. 25 000 • 10.4 (12.5) MNOK in short-term payables. 20 000 • Cash Flow from operations -3.3 MNOK 35 164 31 664 (-10.5 MNOK).
Slide 14: Sales for Q1 in line with expectations
Sales for Q1 in line with expectations Biotec revenues per segment Animal & Consumer Health Amounts in NOK 1.000' ArcticZymes 13 000 Woulgan Segment Q1 Sales ArcticZymes MNOK 7.9 8 000 Animal & Consumer Health MNOK 5.7 Woulgan® MNOK 1.2 3 000 Group MNOK 14.8 Q1 2018 Q2 2018 Q3 2018 Q4 2018 Q1 2019 -
Slide 15: EBITDA improvement on a quarterly basis
EBITDA improvement on a quaterly basis EBITDA Operating Expenses Amounts in NOK 1.000' Q1 2018 Q2 2018 Q3 2018 Q4 2018 Q1 2019 1 000 Personell expenses 0 Property, plant and equipment -1 000 IT -2 000 External services -3 000 Marketing and sales -4 000 License, patent and -5 000 trademark Other oper
Slide 16: ArcticZymes performance
ArcticZymes performance Enzymes Q1 YTD • Improvement of 1.6 MNOK in Q1 sales 2019 2018 2019 2018 (Amounts in NOK 1.000) compared to Q1 2018. Sales revenues 7.869 6.337 7.869 6.337 Operating expenses -8.885 -7.625 -8.885 -7.625 • Operating expenses increased due to EBITDA -242 -377 -242 -377 personne
Slide 17: BetaGlucans performance
BetaGlucans performance BetaGlucans Q1 YTD (Amounts in NOK 1.000) 2019 2018 2019 2018 • Sales continue to be driven by Animal Health Sales revenues 6.947 7.905 6.947 7.905 but less than previous quarters. Gross profit 4.152 3.633 4.152 3.633 Operating expenses -6.521 -7.935 -6.521 -7.935 • Reduced e
Slide 18: Outlook
Outlook
Slide 19: Outlook 2019
Outlook 2019 • Management expect revenue growth in the two focus areas – ArcticZymes and Woulgan® to be strongest in H2 – whilst reducing cash consumption. • ArcticZymes – objectives are to grow business organically, launching new products, whilst seeking inorganic growth opportunities. • Woulgan® –